Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

NCT02087423 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02087423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02087423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 25, 2014
Completion date
March 26, 2025
Enrollment
446 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer